Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designHIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIVCrystal Structure of a Soluble Cleaved HIV-1 Envelope TrimerImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentHIV-1 envelope subregion length variation during disease progressionTemporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody responseHIV-1 Transmission, Replication Fitness and Disease Progression.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domainsBiologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission.Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoproteinRole of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloDifferent regions of HIV-1 subtype C env are associated with placental localization and in utero mother-to-child transmission.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designImpact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.The highly conserved aspartic acid residue between hypervariable regions 1 and 2 of human immunodeficiency virus type 1 gp120 is important for early stages of virus replication.Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid)Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revertCooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cellsAntibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposureResistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
P2860
Q24679395-BD79A02A-6FD5-4043-BBD4-E0ECE87B1918Q27497560-34F0F6C9-E402-4403-94D7-327EEDBC22A8Q27680496-161B8273-9E9B-4A57-85DE-D6280AAAB863Q28478943-BEA0C4DE-30C7-41BC-99D5-40BF7B705D7CQ30355260-F3D66E28-B435-4BDD-89C2-B9A928172CA0Q30397933-1274862D-B229-4F5A-9D29-40D068D005BEQ33664910-DB1C71BA-A05D-4A7A-B57D-55BCAD7EC326Q33758570-1101348D-C985-4C44-BCBD-E51B9552EBA5Q33788792-D83B38CF-C21B-44C9-A5CF-8879651BED1FQ33796067-CCD2B9E8-481D-4B68-A79B-BD6AC732A9E6Q33843723-ECC5356A-1D50-42D4-908F-BD61E0F0A6D4Q33851094-3C75E122-6AE1-487D-9BC3-069BC219C0DBQ33851405-CCAF312A-3F73-48C6-B2C7-6646164F20F6Q33980469-CFAF9BF4-C5F7-469B-B559-A3959B0DA16AQ34121239-1567EFFF-DD29-4925-BA7D-33132E898793Q34292765-FEE6D595-E14B-4511-BCF1-D6F87D167883Q34301803-E9944E7C-95A8-4C1C-A5C2-2CB39740394FQ34309493-0EB4446F-6AEA-40DD-9648-D1F785DF5C4DQ34338411-729E88DB-6F71-4C49-94C4-2EB8606C1EA4Q34347265-BFCE3C5F-8E3A-456F-A806-C619FF65C491Q34998032-A1E6222D-BE7C-49A6-A628-455C90F8AF00Q35024202-8668EC91-12D6-4802-BAA4-81E1332171FCQ35077772-6B282326-B312-4417-87D1-3637D9C2BAC0Q35196671-DBAD0C22-C928-44A9-BA9E-22F6006F112FQ35785244-614694E6-F2CF-45F0-AA39-5994E70F601DQ35830393-D98BAA62-D598-49DF-8D3D-62E5E20DC2CEQ35835261-39CDB9F0-6547-4136-ACFF-4B5B689C8A5BQ35837553-8EDC7353-A661-4D1A-8DF4-6D86EC7FED34Q35838430-970E40DF-B6FB-4BBE-8015-6C5D9EA5BB83Q35838613-47FA2D14-9309-4C03-B9E6-6EF82F7070F4Q35845976-17FF5A9D-0748-4DA3-B9F7-238A4257597DQ35846005-446BB874-015F-46DB-8E65-A1BE754F5E5FQ35848446-95B92F21-11F0-4BB9-8B14-DAFB4401A052Q35853972-FE5CB3B1-1652-4199-BDB8-D9FAF7F52621Q35855710-CDCBFAA6-7927-4AD0-BFE2-DD61F795F14DQ35857331-0AF6F56E-4396-406E-AE28-97189656BDBFQ35870879-13783053-82F0-44F8-A99C-38B4529B9ACEQ35870903-EB215EED-9B3D-4AFE-A654-A1D7B5AE9236Q35873306-F82333B2-953B-4A28-AD37-4848ABFF4BAFQ35892184-FA139194-4F96-4E1D-A074-FCF110D229BF
P2860
Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Effect of amino acid changes i ...... on by a neutralizing antibody.
@ast
Effect of amino acid changes i ...... on by a neutralizing antibody.
@en
type
label
Effect of amino acid changes i ...... on by a neutralizing antibody.
@ast
Effect of amino acid changes i ...... on by a neutralizing antibody.
@en
prefLabel
Effect of amino acid changes i ...... on by a neutralizing antibody.
@ast
Effect of amino acid changes i ...... on by a neutralizing antibody.
@en
P2093
P2860
P1433
P1476
Effect of amino acid changes i ...... ion by a neutralizing antibody
@en
P2093
P2860
P304
P407
P50
P577
1993-06-01T00:00:00Z